Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo-Neo T2DM study.

These reductions are statistically highly significant, but more importantly, clinically relevant in terms of prevention of diabetic complications associated with poor glycaemic control. 13 Moreover, 48.1% of all FAS2‐M12 completers achieved the combined primary endpoint defined as reaching their individual HbA 1c target or an FPG of ≤110 mg/dL within 12 months.

also in 132,142 other papers